HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Maintenance therapy with interferon-alpha 2b, cyclophosphamide, and prednisone in aggressive diffuse large cell lymphoma.

Abstract
Maintenance therapy in patients with aggressive malignant lymphoma using biological modifiers remains uncertain. We conducted a controlled clinical trial to evaluate the efficacy and toxicity of interferon-alpha 2b, cyclophosphamide, and prednisone as maintenance therapy in patients with aggressive diffuse large B cell lymphomas in complete remission after aggressive chemotherapy. In an intent-to-treat analysis, 169 patients were eligible for this study; the end points were event-free survival (EFS) and overall survival (OS). With a median follow-up of 49.3 months, no statistical differences were observed and actuarial curves at 5 years showed that EFS was 71% (95% confidence interval [CI], 63-79%) for patients who received maintenance compared to 63% (95% CI, 59-71%) for patients in control group (p = 0.05). No statistical differences were observed in OS between maintenance arm: 84% (95% CI, 78-89%) and control group 83% (95% CI, 77-88%) in control group (p = 0.2). All patients received the maintenance therapy as planned and in time, thus dose intensity was considered 1.0 in all cases. Acute toxicity was mild, and no delay or suspension of treatment was necessary. Late toxicity was not evident until now. We conclude that use of maintenance therapy combining interferon-alpha 2b, cyclophosphamide, and prednisone is not useful in patients with aggressive lymphoma if they had been treated with aggressive combined chemotherapy.
AuthorsAgustin Avilés, Natividad Neri, M Jesús Nambo, Claudia Castañeda, Alejandra Talavera, Judith Huerta-Guzmán, Edgar Murillo
JournalStem cells and development (Stem Cells Dev) Vol. 13 Issue 2 Pg. 205-9 (Apr 2004) ISSN: 1547-3287 [Print] United States
PMID15186737 (Publication Type: Clinical Trial, Controlled Clinical Trial, Journal Article)
CopyrightCopyright Mary Ann Liebert, Inc.
Chemical References
  • Interferon alpha-2
  • Interferon-alpha
  • Recombinant Proteins
  • Cyclophosphamide
  • Prednisone
Topics
  • Adult
  • Aged
  • Cyclophosphamide (adverse effects, therapeutic use)
  • Disease-Free Survival
  • Drug Therapy, Combination
  • Female
  • Follow-Up Studies
  • Humans
  • Interferon alpha-2
  • Interferon-alpha (adverse effects, therapeutic use)
  • Lymphoma, Large B-Cell, Diffuse (drug therapy, pathology)
  • Male
  • Middle Aged
  • Prednisone (adverse effects, therapeutic use)
  • Recombinant Proteins

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: